# Amylyx Pharmaceuticals, Inc.

**AMLX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001658551

**C/D**

**on the C/D boundary of 369 graded peers in healthcare**

rank 227 of 369; percentile 61.4; sampling error 2.5 points; lower is stronger




**C/D, the tortoise**



| Scoreboard | |
|---|---|
| **Profitability** | D<br>percentile 71.7 |
| **Solvency** | A/B<br>percentile 21.1 |
| **Growth and financing** | D<br>percentile 63.5 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $332.6M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | degenerate inputs<br>not computable: fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 3, 2026<br>254 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026 |
| **Last close** | $31.77<br>2026-11-11; market equity $4.1B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 3, 2026*

Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality. Our current pipeline is represented in the table below.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 71.7** | | | | | | |
| Gross profitability | 0.0% | 32.3% | | 95.7 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (8.1%) | (6.6%) | | 47.6 | 801 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 4* | | | | | | |
| **Solvency, sleeve percentile 21.1** | | | | | | |
| Twelve-month failure probability | 0.08% | 0.08% | | 41.9 | 247 | 2026-09-30 |
| Altman Z double-prime | 7.18 | (0.35) | | 13.4 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 14.27x | 2.95x | | 8.1 | 827 | 2025-12-31 |
| **Growth and financing, sleeve percentile 63.5** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *current value must be positive and the base must exceed $100,000* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | (5.3%) | 2.2% | | 62.8 | 695 | 2025-12-31 |
| Net share issuance, one year | 24.8% | 2.5% | | 64.1 | 628 | 2026-02-23 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 222 | ARS Pharmaceuticals, Inc. (SPRY) | 60.1 | C/D | short runway |
| 223 | Tango Therapeutics, Inc. (TNGX) | 60.3 | C/D | dilution |
| 224 | Cryoport, Inc. (CYRX) | 60.6 | C/D | late filer |
| 225 | Teva Pharmaceutical Industries Ltd. (TEVA) | 60.9 | C/D | |
| 226 | Akebia Therapeutics, Inc. (AKBA) | 61.1 | C/D | fortress balance sheet |
| 227 | Amylyx Pharmaceuticals, Inc. (AMLX) | 61.4 | C/D | degenerate inputs |
| 228 | Embecta Corp. (EMBC) | 61.7 | C/D | late filer |
| 229 | Biogen Inc. (BIIB) | 62.0 | C/D | |
| 230 | Beam Therapeutics Inc. (BEAM) | 62.2 | C/D | |
| 231 | Cardiff Oncology, Inc. (CRDF) | 62.5 | C/D | short runway, fortress balance sheet |
| 232 | AbbVie Inc. (ABBV) | 62.8 | D | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-11-11 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 108.9% | (1.9%) | 92 |
| Distance from 52-week high | (19.8%) | (27.8%) | 59 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | (3.0%) | (1.0%) | 44 |
| Book value to price | 0.18 | 0.27 | 38 |
| Sales to price | 0.00 | 0.29 | 0 |
| Composite equity issuance, five years | not computable | 20.8% | |
| Relative strength against the sector, log excess return | 0.57 | (0.19) | 92 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $240.1M |
| Operating cash flow, four quarters | -$129.9M |
| Months of runway | 22.2 |
| Days since last periodic filing | 7 (10-Q received Nov 5, 2026) |
| Median daily dollar volume, 63 sessions | $42.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $0 | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 3 | assets | us-gaap:Assets | $332.6M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 4 | net income | us-gaap:NetIncomeLoss | -$144.7M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$123.3M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 6 | assets | us-gaap:Assets | $193.6M | 2024-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 7 | current assets | us-gaap:AssetsCurrent | $323.7M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $22.7M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$751.4M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$153.3M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 11 | book equity | us-gaap:StockholdersEquity | $305.3M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 12 | liabilities | us-gaap:Liabilities | $27.4M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $87.4M | 2024-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $380.8M | 2023-12-31 | 2025-03-04 | 10-K | 25-031309 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $22.2M | 2022-12-31 | 2024-02-22 | 10-K | 24-018447 |
| 16 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $138,000 | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 17 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$167.6M | 2024-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 18 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $157,000 | 2024-12-31 | 2026-03-03 | 10-K | 26-086645 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $11.9M | 2023-12-31 | 2025-03-04 | 10-K | 25-031309 |
| 20 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.2M | 2023-12-31 | 2025-03-04 | 10-K | 25-031309 |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$179.9M | 2022-12-31 | 2024-02-22 | 10-K | 24-018447 |
| 22 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.5M | 2022-12-31 | 2024-02-22 | 10-K | 24-018447 |
| 23 | depreciation amortization | us-gaap:Depreciation | $525,000 | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 24 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$144.7M | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 25 | income tax | us-gaap:IncomeTaxExpenseBenefit | $46,000 | 2025-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 26 | current assets | us-gaap:AssetsCurrent | $189.4M | 2024-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 27 | current liabilities | us-gaap:LiabilitiesCurrent | $28.4M | 2024-12-31 | 2026-03-03 | 10-K | 26-086645 |
| 28 | assets | us-gaap:Assets | $517.5M | 2023-12-31 | 2025-03-04 | 10-K | 25-031309 |
| 29 | assets | us-gaap:Assets | $391.5M | 2022-12-31 | 2024-02-22 | 10-K | 24-018447 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 110,536,944 | 2026-02-23 | 2026-03-03 | 10-K | 26-086645 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 88,602,468 | 2025-02-28 | 2025-03-04 | 10-K | 25-031309 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.